Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2005, for Bioanalytical Systems, Inc. (Note: The request metadata lists "Inotiv, Inc.", but the filing text identifies the registrant as Bioanalytical Systems, Inc.). The company operates in two segments: Services (laboratory and analytical support for pharmaceutical development) and Products (scientific instruments for medical research). The fiscal year ends September 30.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2005 | Nine Months Ended June 30, 2005 |
|---|---|---|
| Total Revenue | $11.3 million | $30.1 million |
| Gross Profit | $5.0 million (44.5% margin) | $11.2 million (37.2% margin) |
| Operating Income | $0.9 million | $0.9 million |
| Net Income (Loss) | $0.4 million | $(0.1) million |
| Cash and Equivalents | $1.0 million (as of June 30, 2005) | |
| Long-Term Debt | $13.5 million (excluding current portion) | |
| Available Credit | ~$3.2 million under revolving facility |
Material Changes vs. Prior Period
- Revenue Mix Shift: Total revenue increased 6% in the quarter and 7% year-to-date. This growth was driven by a 24% increase in Service revenue, offset by a 24% decline in Product revenue due to softness in the Culex product line and sporadic large orders.
- Operating Expenses: General and administrative (G&A) expenses surged 52% in the quarter (to $3.1 million) and 37% year-to-date. This was primarily due to the transition from owning to leasing the Baltimore facility (increasing rent and operating costs) and depreciation on new facilities.
- Profitability: While the company reported a net income of $356,000 for the quarter, it reported a net loss of $137,000 for the nine-month period, compared to a net income of $2,000 in the prior year. The nine-month loss was driven by US income taxes exceeding consolidated pre-tax income.
- Cash Flow: Operating cash flow turned negative ($0.7 million used) due to increased investments in accounts receivable and inventory. However, investing activities provided $4.3 million in cash from the sale of the Baltimore building.
Guidance, Outlook, and Risks
- Capital Expenditures: Management expects total capital additions for the fiscal year to range between $2.0 million and $2.5 million, with $1.5 million financed via capital leases.
- Liquidity: The company does not foresee a need for extensive borrowing under its revolving credit agreement, except to finance rapid growth in receivables and inventory. The revolving line expires December 31, 2007.
- Internal Controls: Management disclosed that disclosure controls and procedures were not effective as of June 30, 2005. This was due to the ongoing conversion to a new centralized Enterprise Resources Planning (ERP) system. While the system is now in use, debugging and refinement are ongoing.
- Market Risks: The company is exposed to interest rate fluctuations and foreign currency exchange rates, though management estimates a 10% adverse change in either would not materially affect results.
Investor Verification Checklist
- ERP Implementation Status: Verify the timeline for fully debugging the new ERP system and the resolution of internal control deficiencies.
- Product Segment Recovery: Monitor the Culex product line for signs of recovery, as product revenue remains significantly depressed compared to the prior year.
- Debt Covenants: Confirm continued compliance with debt covenants, specifically the interest-bearing indebtedness to EBITDA ratio, given the recent increase in G&A expenses.
- Leaseback Obligations: Review the impact of the $2.8 million letter of credit required for the Baltimore building leaseback on available borrowing capacity.